Pharmacodynamics xanthine derivatives. It improves trenbolone acetate 100mg the microcirculation in the areas of impaired circulation. It improves blood rheology (flow) due to the impact on pathologically altered deformability of red blood cells, increases the elasticity of erythrocyte membranes trenbolone acetate 100mg inhibits the aggregation of platelets and red blood cells and reduces the increased blood viscosity. The mechanism of action is associated with inhibition of phosphodiesterase and the accumulation of cyclic adenosine monophosphate (cAMP) in the cells of vascular smooth muscles and elements of blood. trenbolone acetate 100mg inhibits aggregation of red blood cells and platelets reduces the level of fibrinogen in plasma and enhances fibrinolysis, reducing blood viscosity and improves its flow trenbolone acetate 100mg characteristics. It improves oxygen supply to areas of impaired blood circulation, particularly in the limbs, the central nervous system, and to a lesser extent in the kidneys. In peripheral arterial occlusive disease ( “intermittent” claudication) leads to an increase in walking distance, elimination of night cramps calf muscles, reduce pain at rest. In case of violation of cerebral circulation improves symptoms. Providing myotropic weak vasodilating effect, somewhat reduces the total peripheral vascular resistance and slightly dilates coronary vessels.
Following oral trenbolone acetate 100mg is almost completely absorbed from the gastrointestinal tract. Prolonged form provides sustained release and uniform absorption. trenbolone acetate 100mg is metabolized in the liver “first-pass”, thereby forming two pharmacologically active metabolite 1-5-hydroxyhexyl-3,7-dimethylxanthine (metabolite I) and 1-3-carboxypropyl-3,7-dimethylxanthine (metabolite V ). The concentration of metabolite I and V, respectively, in the plasma 5 and 8 times higher than that of trenbolone acetate 100mg. The ingestion of tablets Vazonita maximum concentration of trenbolone acetate 100mg and its active metabolites in plasma is achieved in 3-4 hours and is maintained at a therapeutic level of about 12 hours. The drug is excreted mainly (94%) by the kidneys as metabolites. Provided with breast milk. In severe renal impairment the excretion of metabolites is slowed down. If abnormal liver function observed lengthening half-life and increased bioavailability.
- Violation of peripheral blood circulation in the background of atherosclerosis, diabetes and inflammatory processes (including in the “intermittent” claudication due to atherosclerosis, diabetic angiopathy, obliterative endarteritis);
- Acute and chronic cerebral circulatory disorders of ischemic origin;
- Symptomatic treatment of the consequences of cerebral circulatory disorders of atherosclerotic (impaired concentration, dizziness, memory impairment);
- Atherosclerotic and encephalopathy; angiopathy (paresthesia, Raynaud’s disease);
- Trophic disorders of tissues as a result of violations of arterial or venous microcirculation (trophic ulcers, post-thrombotic syndrome, frostbite, gangrene);
- Circulatory disorders in the eye blood vessels (acute and chronic circulatory failure in the network or in the choroid);
- Disorders of the middle ear function of vascular origin, accompanied by hearing loss.
- Hypersensitivity to trenbolone acetate 100mg, other methylxanthine derivatives or other components that are part of the drug;
- Acute myocardial infarction;
- Massive bleeding;
- Bleeding in the retina of the eye;
- Acute hemorrhagic stroke;
- The period of breast-feeding;
- Age 18 years (effectiveness and safety have been established).
Application of pregnancy and during breastfeeding
Use of the drug during pregnancy and during breast-feeding is contraindicated.
Precautions : cerebral arteriosclerosis and / or coronary vessels, especially in cases of hypotension and cardiac arrhythmias; chronic heart failure, hepatic insufficiency, renal insufficiency (creatinine clearance less than 30 ml / min -. cumulation of risk and an increased risk of side effects), gastric ulcer and duodenal ulcers, has recently undergone surgical intervention (risk of bleeding), increased tendency to bleeding For example, when using anticoagulants, or in violation of blood coagulation (risk of heavier bleeding).
Dosing and Administration
Pot Tablets ® is taken orally without chewing, drinking plenty of fluids, preferably after a meal.
The drug is usually prescribed 1 tablet of 600 mg two times a day (morning and evening), the maximum daily dose of 1200 mg.
The duration of treatment and a drug dosing regimen Pot ® installed physician individually, depending on the clinical picture of the disease and the resulting therapeutic effect.
in patients with chronic renal failure (creatinine clearance less than 30 mL / min), the daily dose reduced to 600 mg.
Reducing the dose given individual tolerance necessary in patients with severe hepatic impairment.
Treatment can be initiated with low doses in patients with low blood pressure, as well as in patients who are at risk due to a possible reduction in blood pressure (patients with severe coronary heart disease or with hemodynamically significant stenoses of the cerebral vessels) . In these cases, the dose can be increased only gradually.
On the part of the central nervous system: headache, dizziness, anxiety, sleep disorders, convulsions, there are cases of aseptic meningitis. For the skin and subcutaneous fat: flushing of the face, “tides” of blood to the skin of the face and upper chest , edema, increased fragility of nails. From the digestive system: dry mouth, feeling of pressure and fullness in the stomach, loss of appetite, nausea, vomiting, diarrhea, intestinal atony, aggravation cholecystitis, cholestatic hepatitis. On the part of the organ of vision: blurred vision, scotoma. Cardio-vascular system: tachycardia, arrhythmia, false angina, the progression of angina, lower blood pressure. From the side of hematopoiesis and hemostasis system: bleeding can occur in rare cases (from the mucous membranes, vessels skin, stomach, intestines), and thrombocytopenia, leukopenia, pancytopenia, gipofibrinogenemia, aplastic anemia. In this regard, the treatment of drug Pot ® is necessary to carry out regular monitoring of peripheral blood. Allergic reactions:itching, skin flushing, urticaria, angioedema, anaphylactic shock. Laboratory findings: increased activity of “liver” transaminases: alanine aminotransferase (ALT), aspartate aminotransferase (ACT), and lactate dehydrogenase (LDH) and alkaline phosphatase.
Symptoms: weakness, dizziness, tachycardia, drowsiness, marked reduction in blood pressure, redness of the skin, loss of consciousness, increase in body temperature (fever), areflexia, tonic-clonic seizures, signs of gastrointestinal bleeding (vomiting-type “coffee grounds”). Treatment: gastric lavage, followed by administration of activated charcoal. In the case of vomiting with traces of blood gastric lavage is not allowed. In the future, treatment is symptomatic, aimed at maintaining respiratory function and blood pressure. In convulsions – diazepam.
Interaction with other drugs
trenbolone acetate 100mg may increase the effects of drugs that affect blood clotting (indirect and direct anticoagulants, thrombolytics), antibiotics (including cephalosporins – tsefamandola, cefoperazone, tsefotetan), valproic acid. Increases the effectiveness of antihypertensive drugs, insulin and hypoglycemic agents for oral administration.
Cimetidine increases the concentration of trenbolone acetate 100mg in plasma (the risk of side effects).
Combined use with other xanthines can lead to excessive nervous excitement.
In some patients, concomitant use of trenbolone acetate 100mg and theophylline may cause increasing theophylline concentration (the risk of side effects associated with theophylline).
Patients with severe renal impairment at admission Pot ® need to be especially careful medical supervision. If during treatment in patients having bleeding in the retina of the eye, the drug immediately overturned.
Treatment should be under the control of blood pressure. In patients with low and unstable blood pressure administered dose should be reduced.
In patients with diabetes, taking hypoglycemic agents used in high doses can cause hypoglycemia (dose correction is required). When applied simultaneously with anticoagulants is necessary to monitor the performance of the blood coagulation system, including international normalized ratio (MHO).
In patients who have undergone recent surgery, a systematic monitoring of hemoglobin and hematocrit.
Older people may require dose reduction (increased bioavailability and reduced clearance rate).
Smoking may reduce the therapeutic efficacy of the drug.
Effects on ability to drive vehicles and machines
Due to the possible occurrence of dizziness recommended caution when driving and maintenance of complex mechanisms. During the administration of the drug is not suitable for drinking.